Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

A little more than a third (36.1%) of patients with Huntington disease (HD) and chorea are taking an anti-chorea medication, a study found.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.